|
|
Suppliers for
Laropiprant
|
Properties | CAS |
571170-77-9 | Formula |
C21H19ClFNO4S |
|
|
6 Registered suppliers
Description : a drug used in combination with niacin to reduce blood cholesterol (LDL and VLDL) that is no longer sold - Molecular Weight :435.91
- Melting Point :175°C
- Purity :> 95%
Molecular Formula : C21H19ClFNO4S Canonical SMILES : CS(=O)(=O)C1=C2C(=CC(=C1)F)C3=C(N2CC4=CC=C(C=C4)Cl)C(CC3)CC(=O)O InChI : 1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1 InChIKey : NXFFJDQHYLNEJK-CYBMUJFWSA-N Solubility : Soluble in DMSO Appearance : A crystalline solid Application : A potent, selective DP1 receptor antagonist Storage : Store at -20 °C Synonyms : (3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-cyclopent[b]indole-3-acetic acid
More details are to be found here
Description : a drug used in combination with niacin to reduce blood cholesterol (LDL and VLDL) that is no longer sold - Molecular Weight :435.91
- Melting Point :175°C
- Purity :> 95%
Molecular Formula : C21H19ClFNO4S Canonical SMILES : CS(=O)(=O)C1=C2C(=CC(=C1)F)C3=C(N2CC4=CC=C(C=C4)Cl)C(CC3)CC(=O)O InChI : 1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1 InChIKey : NXFFJDQHYLNEJK-CYBMUJFWSA-N Solubility : Soluble in DMSO Appearance : A crystalline solid Application : A potent, selective DP1 receptor antagonist Storage : Store at -20 °C Synonyms : (3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-cyclopent[b]indole-3-acetic acid
More details are to be found here
|
Properties:
... more properties and specification on Laropiprant
|
|
Privileged suppliers
Last update 2024-06-21
|